# MyeloMATCH (NCT06577441)

> Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06577441
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Myelodysplastic Syndrome
- Interventions: Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Enasidenib
- Enrollment: 54
- Primary outcome: Complete response (CR) rate

## Indexed commentary on MyeloMATCH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on Bluesky
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=myelomatch-nct06577441